Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA (Press release, Molecular Partners, DEC 30, 2022, View Source [SID1234625691]). In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Presentation Details:

JP Morgan 41st Annual Healthcare Conference

Wednesday, January 11, 2023, at 10:30 am ET (4:30 pm CET)
Baader Helvea Swiss Equities Conference

Thursday, January 12, 2023, at 10:00 am ET (4:00 pm CET)
Conference Participation Details:

The Octavian Seminar 2023

Friday, January 13, 2023
All webcasted presentations will be made available on the Molecular Partners website.